<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20110425006281N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-12-29</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Ketamine, Tramadol, and Ondansetron in shiver controlling</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effectiveness of Ketamine, Tramadol and Ondansetron on prevention of shivering due to Spinal Anesthesia in cesarean section surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>508</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/33951</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Patients will be randomized with quadruple blocks and divide into four groups of a low dose of ketamine=A, tramadol=B, Ondansetron=C, and control=D. The randomization unit is individual. In this randomization, we do not have a layer and we use a random numbers table tool. The method of constructing a random sequence is as follows: 
ABCD-ABDC-ACBD-ACDB-ADBC-ADCB-BACD-BADC-BDCA-BDAC-BCAD-BCDA--CABD-CADB-CBAD-CBDA-CDAB-CDBA-DABC-DACB-DCAB-DCBA-DBAC-DBCA-ABCD-ABDC-ACBD-ACDB-ADBC-ADCB-BACD-BADC-BDCA-BDAC-BCAD-BCDA-CABD-CADB-CBAD-CBDA-CDAB-CDBA-DABC-DACB-DCAB-DCBA-DBAC-DBCA-ABCD-ABDC-ACBD-ACDB-ADBC-ADCB-BACD-BADC-BDCA-BDAC-BCAD-BCDA-CABD-CADB-CBAD-CBDA-CDAB-CDBA-DABC-DACB-DCAB-DCBA-DBAC-DBCA-ABCD-ABDC-ACBD-ACDB-ADBC-ADCB-BACD-BADC-BDCA-BDAC-BCAD-BCDA--CABD-CADB-CBAD-CBDA-CDAB-CDBA-DABC-DACB-DCAB-DCBA-DBAC-DBCA-ABCD-ABDC-ACBD-ACDB-ADBC-ADCB-BACD-BADC-BDCA-BDAC-BCAD-BCDA-CABD-CADB-CBAD-CBDA-CDAB-CDBA-DABC-DACB-DCAB-DCBA-DBAC-DBCA-ABCD-ABDC-ACBD-ACDB-ADBC-ADCB-BACD
After providing the list, we will give it to the anesthetic technician to categorize patients in control or treatment groups based on the above list, Blinding description: All drugs and placebo (normal saline) are prepared by an anesthetic technician who is not included in this study and will be coded in 5-millimeter syringes and will be given to the responsible anesthetist. So, In the event of complications (drowsiness, nausea, vomiting, itching, flushing, and hallucination), it will be clear which patient belongs to which Group and if necessary, it will be treated based on the type of complication.
Accordingly, patients, the anesthetist, and the trained person recording items listed in the questionnaire (severity of shivering, Apgar minute one and five and vital signs of patients) are unaware of the type of treatment group.</study_design>
      <phase>3</phase>
      <hc_freetext>Shivering Complication in Spinal Anesthesia in Cesarean Section.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: low dose of ketamine (0.2 milligrams per Kilogram intravenous), (500 milligrams per 10 milliliters of the Stroup pharmaceutical company in Belgium). Immediately after spinal anesthesia, it will be injected to patients. Intervention 2: Intervention group Tramadol (0.5 milligrams per Kilogram intravenous), (50 milligrams per milliliters, Drugpakhsh Pharmaceutical Company). Immediately after spinal anesthesia, it will be injected to patients. Intervention 3: Intervention group Ondansetron (4 milligrams intravenous), (4 milligrams in 2 milliliters produced by Borujerd-Iran General Purpose Pharmacy Company).Immediately after spinal anesthesia, it will be injected to patients. Intervention 4: Control group: 5 milliliters of normal saline will be injected to patients, immediately after spinal anesthesia.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is not decided yet</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Ali Mohammadzadeh Joryabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Heshmat Hospital</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4144654839</zip>
        <telephone>+98 13 3366 9066</telephone>
        <email>alimj1393@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Ali Mohammadzadeh Joryabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Heshmat Hospital</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4144654839</zip>
        <telephone>+98 13 3366 9066</telephone>
        <email>alimj1393@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Pregnant women
Candidates for cesarean section
Under spinal anesthesia
ASA class I, II
Age between 18-39</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>39 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>History of allergy
Prohibition for each of the studied drugs
Addiction to any chemical or natural compound
Psychosis
Having cold
Heart disease
Liver and kidney dysfunction
History of seizure
History of using Monoamine Oxidase inhibitor  in the past 14 days
Severe asthma
Respiratory depression
The initial temperature of the patient`s body is above 38 Celsius or the central temperature is less than 36 Celsius
Getting any medication that changes the thermoregulation
Weight over 100 Kilograms and below 50 Kilograms
History of using vasodilator
Cases requiring sedation or having intravenous administration due to partial spinal anesthetics
A condition that temperature cannot be maintained due to equipment problems in heating and cooling systems</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O74.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other complications of spinal and epidural anesthesia during labor and delivery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: low dose of ketamine (0.2 milligrams per Kilogram intravenous), (500 milligrams per 10 milliliters of the Stroup pharmaceutical company in Belgium). Immediately after spinal anesthesia, it will be injected to patients.</i_keyword>
      <i_keyword>Intervention group Tramadol (0.5 milligrams per Kilogram intravenous), (50 milligrams per milliliters, Drugpakhsh Pharmaceutical Company). Immediately after spinal anesthesia, it will be injected to patients.</i_keyword>
      <i_keyword>Intervention group Ondansetron (4 milligrams intravenous), (4 milligrams in 2 milliliters produced by Borujerd-Iran General Purpose Pharmacy Company).Immediately after spinal anesthesia, it will be injected to patients.</i_keyword>
      <i_keyword>Control group: 5 milliliters of normal saline will be injected to patients, immediately after spinal anesthesia.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of shivering. Timepoint: Every 5 minutes during surgery and every 15 minutes in 45 minutes of recovery time, the intensity of shivering will be recorded. Method of measurement: Shivering classification table.</prim_outcome>
      <prim_outcome>Baby`s Apgar Minute One and five. Timepoint: Minute  one and five of  baby's birth. Method of measurement: Based on Apgar Assessment Table.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rasht University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-09-01</approval_date>
        <contact_name>Ethics Committee Of Guilan University Of Medical Sciences</contact_name>
        <contact_address>Vice Chancellor for research, Shahid Siadati Avenue, Namjoo Street Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
